MD-4251

• Description:

  MD-4251 is an orally active MDM2 PROTAC degrader. MD-4251 potently degrades MDM2 in RS4;11 cells (DC50: 0.2 nM) and actives p53. MD-4251 shows strong antiproliferative activity against acute leukemia cells (wild-type p53) with minimal efficacy in mutant type. MD-4251 induces complete tumor regression in RS4;11 xenograft mice model[1]. Pink: MDM2 ligand (HY-130684) ; Blue: CRBN ligase ligand (HY-W883326) ; Black: linker

• UNSPSC:

  12352005

• Target:

  Casein Kinase; IKZF Family; MDM-2/p53; PROTACs

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; PROTAC; Stem Cell/Wnt

• Field of Research:

  Cancer

• Smiles:

  O=C1NC2=CC(Cl)=CC=C2[C@]13C4(CCCCC4)N[C@H]([C@@H]3C5=CC=CC(Cl)=C5F)C(N[C@@H]6CC[C@H](CC6)CN7CCN(CC7)C8=CC=C9C(N(N=C9C%10C(NC(CC%10)=O)=O)C)=C8)=O

• Molecular Formula:

  C47H53Cl2FN8O4

• Molecular Weight:

  883.88

• References & Citations:

  [1]Acharyya RK, et al. MD-4251: A First-in-Class Oral MDM2 Degrader Inducing Complete Tumor Regression with Single-Dose Administration. J Med Chem. 2025 Jul 10;68 (13) :13249-13267.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CK1; IKZF1; MDM2